1. Editorial

2024, as the year is nearing its end, the world stands between hope and challenge in regards to implementing the changes and actions needed to preventing, managing and controlling antimicrobial resistance (AMR) to which the United Nations members committed themselves at the UN General Assembly in New York in September.

Denmark, with its long-standing tradition of high-quality diagnostics, robust health data systems and effective public health responses, is well-positioned to endorse some of the agreed actions. Denmark also has strong experience in working across the human and animal sectors in an integrating One Health approach, which offers a unique opportunity to support both national and global efforts against AMR. Finally, Denmark is characterized by flat hierarchical structures and a strong collaborative spirit in the planning, coordination and response to possible AMR threats.

2023, the year of the data collected and presented in this DANMAP report, seems to be an equally important year. While 2022 was a year pulling out of the COVID-19 pandemic, having to enforce, strengthen and reorganize much of health care systems and work, 2023 saw proof of the former years investigations into antibiotic stewardship and infection prevention and control programs. Although nothing seems to be fully back to normal yet, the trends in the report start picking up at where we left in 2019. An example are continued efforts at long-term care facilities in working with better prevention of infections in the elderly, which are demonstrated by a reduced antibiotic usage and fewer infections than in former years. Another example is the continued reductions in use of the antibiotics of "special critical interest", cephalosporins and fluoroquinolones, at hospitals.

But not everything is solely positive, as demonstrated by a higher use of antibiotics in practically all other age groups than the elderly, continuously increasing use of piperacillintazobactam at hospitals, or the backlash in resistance in *E. coli* and *K. pneumoniae* in clinical samples after years of overall decreasing trends. 2023 also found an increase in the number of outbreaks with Carbapenemase-producing Enterobacterales at Danish hospitals, which demands increased screening, cleaning and other preventive efforts.

The veterinary side also saw interesting changes in 2023, which should not be left unnoticed. Following the ban of zinc oxide in the pig production from June 2022, increases were observed in usage of antimicrobials in weaners, leading to marked increases for aminoglycosides, particularly neomycin and apramycin, and a seemingly direct association to observed increasing resistance levels to the different types of aminoglycosides, particularly neomycin and gentamicin, in haemolytic *E. coli* and *Salmonella enterica* recovered from pigs.

It remains positive that no clear association could be found in analyses investigating the dispersion of resistance genes (Extended spectrum beta-lactamases, ESBL) and sequence types among bacterial strains of *E. coli* from invasive cases in humans and healthy animals, which points towards only little if any direct transmission between the examined populations. However, further genomic analysis of the isolate collection has identified some ESBL genes with probable zoonotic links, which calls for further research.

In conclusion, in 2023 Denmark continued overall low trends of resistance in bacterial strains, and a comparably low usage of antimicrobials in both the veterinary and human sector, but this should not be misinterpreted as "nothing needs to be done". Continuously low levels of antibiotic resistance demand continuous efforts in prevention and rational antibiotic use. High output of pigs produced demands high and sustained input of initiatives ensuring animal health and biosecurity. Movements of goods and people across countries with varying levels of AMR demand attention and screening efforts.

All countries are now - again - encouraged to work with national action plans in a One Health approach. The Danish Veterinary and Food Administration recently published their newest version, the human side is in a consultation process regarding theirs. What is left to do is to renew the Danish One Health AMR Strategy, the overarching umbrella needed upon all efforts.

The DANMAP team

Acknowledgements

DANMAP is based on a strong collaboration between several institutions and on the contributions from highly skilled staff from many specialties and professions. Without their knowledge and engagement, there would be no DANMAP surveillance.

The DTU National Food Institute would like to thank the following:

- The meat inspection staff and company personnel at the participating slaughterhouses for collecting samples from animals at slaughter
- The staff of local Veterinary and Food inspections units for collecting food and animal samples
- The staff of the Danish Veterinary and Food Administration's Laboratory, Ringsted for analysing animal and food samples
- The Danish Veterinary and Food Administration's Food and Feed Safety Division, for collecting and transmitting data on antimicrobial resistance in food and animal samples and for discussing data interpretation
- The Danish Veterinary and Food Administration's Animal Medicine and Veterinary Trade Division, for collecting and transmitting data on veterinary consumption of antimicrobial agents from VetStat and discussing the interpretation of the data
- The Danish Agriculture and Food Council for collaboration regarding the estimation of live biomass of production animals
- Statistics Denmark for providing data necessary for the estimation of live biomass of poultry
- The Danish Aquaculture Producer Organisation for providing data necessary for the estimation of live biomass of fish
- Colleagues at the National Food Institute, DTU, for valuable discussions on many topics related to the report
- All data providers for textboxes and textbox authors

Statens Serum Institut would like to thank the following:

- The Departments of Clinical Microbiology and the DANRES group - Danish Study Group for Antimicrobial Resistance Surveillance - for providing data on resistance in bacteria from human clinical samples and discussing many of the topics included in the report
- The staff of the Neisseria and Streptococcus Typing Unit at SSI for providing data on samples and resistance in betahaemolytic streptococci, H. influenzae and Neisseria gonorrhoeae
- The staff of the Foodborne Pathogens Unit at SSI for providing data on resistance in *Campylobacter* and *Salmonella* from human clinical isolates
- The staff of the Staphylococcus Laboratory at SSI for providing data on invasive staphylococcal infections as well as all MRSA
- The staff of the Antimicrobial Resistance Reference Laboratory and Surveillance Unit at SSI for providing data on resistance in the referred E. coli, K. pneumoniae, A. baumannii, P. aeruginosa and vancomycin and linezolid-resistant enterococci
- The staff at the Unit of Mycology at SSI for providing resistance data for human Candida and Aspergillus
- Colleagues at the Infectious Disease Epidemiology & Prevention Unit at SSI
- Colleagues at the Data Integration and Analysis Secretariat at SSI
- The Danish Health Data Authority and the Register of Medicinal Products Statistics for providing data on antimicrobial consumption on healthcare activity
- All Danish hospital pharmacies for providing data on antimicrobials consumed at hospitals through special deliverances